A Phase 1 Study of 99mTc-p5+14 in Healthy Volunteers and Patients With AL or ATTR Systemic Amyloidosis

PHASE1RecruitingINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

July 31, 2023

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2025

Conditions
Systemic Amyloidosis
Interventions
DRUG

99mTc-p5+14 is an amyloid reactive peptide labeled with technetium-99m.

Peptide p5+14 is a pan-amyloid reactive, synthetic 45 L-amino acid polypeptide with a net +12 positive charge that can bind two major components of all extracellular amyloid deposits: (i) hypersulfated heparan sulfate glycosaminoglycans (proteoglycans) and (ii) amyloid fibrils. The polypeptide, labeled with iodine-124, has been shown (study AMY1001) to bind amyloid in all organs including the heart. This study will evaluate a Tc-99m-labeled version of the peptide for gamma imaging.

DRUG

99mTc-Pyrophosphate and 99mtc-p5+14 - an Amyloid Reactive Peptide Labeled With Technetium-99m.

99mTc-PYP is an FDA-approved, commercially available bone-seeking radiotracer used routinely in nuclear medicine. 99mTC-PYP imaging is used clinically for the diagnosis of cardiac ATTR amyloidosis.

Trial Locations (1)

37920

RECRUITING

University of Tennessee Graduate School of Medicine, Knoxville

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Attralus, Inc.

INDUSTRY

lead

University of Tennessee Graduate School of Medicine

OTHER

NCT05951816 - A Phase 1 Study of 99mTc-p5+14 in Healthy Volunteers and Patients With AL or ATTR Systemic Amyloidosis | Biotech Hunter | Biotech Hunter